hummmmmm,,,,,,,,,,,,,,,our main issue around financing stems from the past number of years of failing miserably to increase share price over that course of time! ,thats the bottom line,,,,established companies of all sorts do fund raising at times,,,,we have discussed the fact that some pre-clinic companies carry market caps in the billions,,,,,why not us??,,,,,,one cannot blame any major investor for taking advantage of the depressed share price at this stage. The risk/reward maybe skewed to the, less risk with increased reward, weighting at this time.

The TSX review I feel will be a matter of formality!,,,HL had no choice but to let shaft out on this one and there must be a back room deal existing where KD is to enter the play once again later increasing his % ownership of this company.  Remember DM noted way back that KD said he was willing to take 208 to the finish line!!,, We must assume that has not changed so KD undoubtedly is still well positioned to continue gaining % ownership later. And we know more $$$ are required so look for KD to be entering when that time comes. And again,,the shares will be placed into Easterns' holding at this depressed mid $1 to $2 level cuz KD aint paying a nickle more than what HL has!!

It certainly looks like RVX will be consumed by these insiders sooner rather than later as these majors will basically own this company from bottom up. So why be a public company??,,both insiders have the funds and being on an index is only a nusiance!,,,what a windfall for humanity and these insiders if we are successful with epigenetcs...!!,,,,jmo